No Data
Mizuho Securities Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating
Adaptimmune Therapeutics Analyst Ratings
European Equities Traded in the US as American Depositary Decline Slightly in Tuesday Trading
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.5
Promising Future for Adaptimmune Therapeutics: Buy Rating Supported by Breakthrough Therapies and Strong Financial Position
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)